Adam Bonislawski

3 weeks ago | genomeweb.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million. The guidance, which excludes revenue from its Lucent Diagnostics business and the expected acquisition of Akoya Biosciences, would represent a year-over-year decline of 5 percent to 13 percent.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – Reform of the Protecting Access to Medicare Act (PAMA) is once again a top priority for the clinical lab industry, but chaos in Washington D.C. could make legislative action a hard lift. And while in each of the last six years, Congress has passed one-year delays to PAMA reporting requirements and reimbursement cuts, such relief could be less likely this year, warned several industry stakeholders last week at the Executive War College (EWC) annual meeting in New Orleans.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – For decades now consolidation has been one of the major trends in the clinical laboratory market as major players like Quest Diagnostics, Laboratory Corporation of America, and Sonic Healthcare have grown their businesses through the acquisition of smaller independent and hospital labs.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – While Quanterix’s amended merger agreement with Akoya Biosciences gives the company’s shareholders a larger stake in the combined firm than did the original terms, some investors have raised concerns that the revised agreement allows Quanterix to execute the deal without putting it to a shareholder vote.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – Quest Diagnostics addressed on Tuesday the effect of the Trump administration's tariffs on its business, characterizing its exposure as "not zero" but "very manageable."During a conference call following release of the company's Q1 2025 financial results, Quest Chairman and CEO Jim Davis said the company spends around $2 billion annually on reagents, supplies, capital equipment, and service contracts.